Another drugmaker halts heartburn drug shipments due to carcinogen

India's Dr. Reddy's Laboratories is the latest drugmaker to stop distribution of ranitidine, the generic version of Zantac, after a potential cancer-causing impurity was found in the drug, according to Bloomberg.

Dr. Reddy's Laboratories stopped worldwide shipments of the heartburn drug ranitidine after the FDA found it contained N-nitrosodimethylamine, which is classified as a probable human carcinogen.

The Italian Drug Agency and Germany's drug regulator will both order a recall of all versions of Zantac with an active ingredient made in India's Saraca Laboratories, according to Bloomberg. Canada has also asked all makers of ranitidine-containing products to stop distribution.

Last week, Sandoz, the generic arm of Novartis, stopped worldwide distribution of its generic version of Zantac.

Sanofi, the maker of the brand-name Zantac medication, has not halted distribution of any ranitidine products outside of Canada.

Read the full report here

More articles on pharmacy:

FDA approves first oral treatment for Type 2 diabetes

FDA finalizes rules to prevent improper petitions from delaying drug approvals

Pharmacists can play key role in preventing Hepatitis A outbreak

More articles on pharmacy:

FDA approves first oral treatment for Type 2 diabetes

FDA finalizes rules to prevent improper petitions from delaying drug approvals

Pharmacists can play key role in preventing Hepatitis A outbreak

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers